CN113861188A - 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用 - Google Patents
吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用 Download PDFInfo
- Publication number
- CN113861188A CN113861188A CN202110966463.3A CN202110966463A CN113861188A CN 113861188 A CN113861188 A CN 113861188A CN 202110966463 A CN202110966463 A CN 202110966463A CN 113861188 A CN113861188 A CN 113861188A
- Authority
- CN
- China
- Prior art keywords
- compound
- phenyl
- prepared
- sup
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940125962 HPK1 kinase inhibitor Drugs 0.000 title abstract description 5
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 75
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims abstract description 26
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000035475 disorder Diseases 0.000 claims abstract description 6
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- -1 benzazepinyl Chemical group 0.000 claims description 112
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 238000010511 deprotection reaction Methods 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 238000006555 catalytic reaction Methods 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 13
- 229910052723 transition metal Inorganic materials 0.000 claims description 13
- 150000003624 transition metals Chemical class 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 238000011065 in-situ storage Methods 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Chemical group 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 claims description 3
- BGDOLELXXPTPFX-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzoxazine Chemical compound C1=CC=C2ONCCC2=C1 BGDOLELXXPTPFX-UHFFFAOYSA-N 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 10
- 150000003222 pyridines Chemical class 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 144
- 238000005160 1H NMR spectroscopy Methods 0.000 description 86
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 83
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 75
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- 102100032306 Aurora kinase B Human genes 0.000 description 4
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 4
- 101000753280 Mus musculus Angiopoietin-1 receptor Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 2
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- LSKYURVDOIDSCG-UHFFFAOYSA-N [4-(4-methylpiperazin-1-yl)phenyl]boronic acid Chemical compound C1CN(C)CCN1C1=CC=C(B(O)O)C=C1 LSKYURVDOIDSCG-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- HIWYFMBSFSTYGU-UHFFFAOYSA-N (2,3-difluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(F)=C1F HIWYFMBSFSTYGU-UHFFFAOYSA-N 0.000 description 1
- SZYXKFKWFYUOGZ-UHFFFAOYSA-N (2,3-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1F SZYXKFKWFYUOGZ-UHFFFAOYSA-N 0.000 description 1
- LOCGPWGCRVKCFN-UHFFFAOYSA-N (2-chloro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(Cl)=C1 LOCGPWGCRVKCFN-UHFFFAOYSA-N 0.000 description 1
- DGFCTCGCMKEILT-UHFFFAOYSA-N (2-ethoxyphenyl)boronic acid Chemical compound CCOC1=CC=CC=C1B(O)O DGFCTCGCMKEILT-UHFFFAOYSA-N 0.000 description 1
- ULUIXJDBPYBAHS-UHFFFAOYSA-N (2-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(F)=C1 ULUIXJDBPYBAHS-UHFFFAOYSA-N 0.000 description 1
- XOVMDVZAWWQSDC-UHFFFAOYSA-N (2-fluoro-6-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(F)=C1B(O)O XOVMDVZAWWQSDC-UHFFFAOYSA-N 0.000 description 1
- QXBWTYBCNFKURT-UHFFFAOYSA-N (2-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=CC=C1B(O)O QXBWTYBCNFKURT-UHFFFAOYSA-N 0.000 description 1
- UHDDEIOYXFXNNJ-UHFFFAOYSA-N (3,4,5-trifluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=C(F)C(F)=C1 UHDDEIOYXFXNNJ-UHFFFAOYSA-N 0.000 description 1
- RULQUTYJXDLRFL-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)boronic acid Chemical compound COC1=CC(B(O)O)=CC(OC)=C1OC RULQUTYJXDLRFL-UHFFFAOYSA-N 0.000 description 1
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- JJRIEFCRGWHLES-UHFFFAOYSA-N (3,5-difluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=C(F)C=C(B(O)O)C=C1F JJRIEFCRGWHLES-UHFFFAOYSA-N 0.000 description 1
- YWUHRGQYLQMLHW-UHFFFAOYSA-N (3,5-difluoro-4-phenylmethoxyphenyl)boronic acid Chemical compound FC1=CC(B(O)O)=CC(F)=C1OCC1=CC=CC=C1 YWUHRGQYLQMLHW-UHFFFAOYSA-N 0.000 description 1
- IBTSWKLSEOGJGJ-UHFFFAOYSA-N (3-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=CC(B(O)O)=C1 IBTSWKLSEOGJGJ-UHFFFAOYSA-N 0.000 description 1
- WJDZZXIDQYKVDG-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(Cl)=C1 WJDZZXIDQYKVDG-UHFFFAOYSA-N 0.000 description 1
- VUTJHOWRPUPHIG-UHFFFAOYSA-N (3-chloro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1Cl VUTJHOWRPUPHIG-UHFFFAOYSA-N 0.000 description 1
- IILGLPAJXQMKGQ-UHFFFAOYSA-N (3-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1F IILGLPAJXQMKGQ-UHFFFAOYSA-N 0.000 description 1
- DQPDLDQJMUGVGI-UHFFFAOYSA-N (3-fluoro-4-phenylmethoxyphenyl)boronic acid Chemical compound FC1=CC(B(O)O)=CC=C1OCC1=CC=CC=C1 DQPDLDQJMUGVGI-UHFFFAOYSA-N 0.000 description 1
- QPXFEWQLALNXEZ-UHFFFAOYSA-N (3-methyl-4-phenylmethoxyphenyl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=C1OCC1=CC=CC=C1 QPXFEWQLALNXEZ-UHFFFAOYSA-N 0.000 description 1
- WIJNYNBSPQMJGO-UHFFFAOYSA-N (3-phenylmethoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(OCC=2C=CC=CC=2)=C1 WIJNYNBSPQMJGO-UHFFFAOYSA-N 0.000 description 1
- UKZVUHVNTYDSOP-UHFFFAOYSA-N (3-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=CC(B(O)O)=C1 UKZVUHVNTYDSOP-UHFFFAOYSA-N 0.000 description 1
- QSWLFBMVIGQONC-UHFFFAOYSA-N (3-propan-2-ylphenyl)boronic acid Chemical compound CC(C)C1=CC=CC(B(O)O)=C1 QSWLFBMVIGQONC-UHFFFAOYSA-N 0.000 description 1
- CEBAHYWORUOILU-UHFFFAOYSA-N (4-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=C(C#N)C=C1 CEBAHYWORUOILU-UHFFFAOYSA-N 0.000 description 1
- IZOOGQYKHWNGOK-UHFFFAOYSA-N (4-cyclopropyloxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1CC1 IZOOGQYKHWNGOK-UHFFFAOYSA-N 0.000 description 1
- QWMJEUJXWVZSAG-UHFFFAOYSA-N (4-ethenylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=C)C=C1 QWMJEUJXWVZSAG-UHFFFAOYSA-N 0.000 description 1
- WRQNDLDUNQMTCL-UHFFFAOYSA-N (4-ethoxyphenyl)boronic acid Chemical compound CCOC1=CC=C(B(O)O)C=C1 WRQNDLDUNQMTCL-UHFFFAOYSA-N 0.000 description 1
- RZCPLOMUUCFPQA-UHFFFAOYSA-N (4-ethylphenyl)boronic acid Chemical compound CCC1=CC=C(B(O)O)C=C1 RZCPLOMUUCFPQA-UHFFFAOYSA-N 0.000 description 1
- PXVDQGVAZBTFIB-UHFFFAOYSA-N (4-methoxy-3-methylphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1C PXVDQGVAZBTFIB-UHFFFAOYSA-N 0.000 description 1
- NQMRYYAAICMHPE-UHFFFAOYSA-N (4-methoxyphenyl)boron Chemical compound [B]C1=CC=C(OC)C=C1 NQMRYYAAICMHPE-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- IVUHTLFKBDDICS-UHFFFAOYSA-N (4-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=C(B(O)O)C=C1 IVUHTLFKBDDICS-UHFFFAOYSA-N 0.000 description 1
- VDUKDQTYMWUSAC-UHFFFAOYSA-N (4-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=C1 VDUKDQTYMWUSAC-UHFFFAOYSA-N 0.000 description 1
- WHDIUBHAKZDSJL-UHFFFAOYSA-N (4-morpholin-4-ylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1N1CCOCC1 WHDIUBHAKZDSJL-UHFFFAOYSA-N 0.000 description 1
- UZRMPSOGFATLJE-UHFFFAOYSA-N (4-pentylphenyl)boronic acid Chemical compound CCCCCC1=CC=C(B(O)O)C=C1 UZRMPSOGFATLJE-UHFFFAOYSA-N 0.000 description 1
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 1
- DMJHEIDWSIAXCS-UHFFFAOYSA-N (4-phenylmethoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCC1=CC=CC=C1 DMJHEIDWSIAXCS-UHFFFAOYSA-N 0.000 description 1
- CJUHQADBFQRIMC-UHFFFAOYSA-N (4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=C1 CJUHQADBFQRIMC-UHFFFAOYSA-N 0.000 description 1
- WLCGYIWOKVWFLB-UHFFFAOYSA-N (4-propylphenyl)boronic acid Chemical compound CCCC1=CC=C(B(O)O)C=C1 WLCGYIWOKVWFLB-UHFFFAOYSA-N 0.000 description 1
- XTVMZKCCFLOJBL-UHFFFAOYSA-N (4-pyrazol-1-ylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1N1N=CC=C1 XTVMZKCCFLOJBL-UHFFFAOYSA-N 0.000 description 1
- HYZNIURBDZXTGX-UHFFFAOYSA-N (4-pyridin-3-ylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=CC=CN=C1 HYZNIURBDZXTGX-UHFFFAOYSA-N 0.000 description 1
- QLVTYWFPUODTBB-UHFFFAOYSA-N (4-pyridin-4-ylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=CC=NC=C1 QLVTYWFPUODTBB-UHFFFAOYSA-N 0.000 description 1
- HNEBXPPPIFWGHH-UHFFFAOYSA-N (4-pyrrolidin-1-ylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1N1CCCC1 HNEBXPPPIFWGHH-UHFFFAOYSA-N 0.000 description 1
- LSQCNEYLDWKDHO-UHFFFAOYSA-N (4-pyrrolidin-1-ylsulfonylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1S(=O)(=O)N1CCCC1 LSQCNEYLDWKDHO-UHFFFAOYSA-N 0.000 description 1
- MNJYZNVROSZZQC-UHFFFAOYSA-N (4-tert-butylphenyl)boronic acid Chemical compound CC(C)(C)C1=CC=C(B(O)O)C=C1 MNJYZNVROSZZQC-UHFFFAOYSA-N 0.000 description 1
- NRPZMSUGPMYBCQ-UHFFFAOYSA-N (4-trimethylsilylphenyl)boronic acid Chemical compound C[Si](C)(C)C1=CC=C(B(O)O)C=C1 NRPZMSUGPMYBCQ-UHFFFAOYSA-N 0.000 description 1
- FMBVAOHFMSQDGT-UHFFFAOYSA-N (5-chloro-2-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(Cl)C=C1B(O)O FMBVAOHFMSQDGT-UHFFFAOYSA-N 0.000 description 1
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical class C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 1
- LTWFBZQFHPDLNU-UHFFFAOYSA-N 2,3-dihydro-1h-pyrido[2,3-b][1,4]oxazine Chemical compound C1=CC=C2NCCOC2=N1 LTWFBZQFHPDLNU-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- SJGGDZCTGBKBCK-UHFFFAOYSA-N 3-acetylphenylboronic acid Chemical compound CC(=O)C1=CC=CC(B(O)O)=C1 SJGGDZCTGBKBCK-UHFFFAOYSA-N 0.000 description 1
- ZBPXFBHBTCYAQS-UHFFFAOYSA-N 5-bromo-3-iodo-2h-pyrazolo[3,4-b]pyridine Chemical compound C1=C(Br)C=NC2=NNC(I)=C21 ZBPXFBHBTCYAQS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LJWZSXDLNMOUIP-UHFFFAOYSA-N N1C=CN=C2N=CC=C21 Chemical class N1C=CN=C2N=CC=C21 LJWZSXDLNMOUIP-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- DDHUSSNOKNYLAI-UHFFFAOYSA-N [3-(diethylcarbamoyl)phenyl]boronic acid Chemical compound CCN(CC)C(=O)C1=CC=CC(B(O)O)=C1 DDHUSSNOKNYLAI-UHFFFAOYSA-N 0.000 description 1
- UWDFWVLAHRQSKK-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(OC(F)(F)F)=C1 UWDFWVLAHRQSKK-UHFFFAOYSA-N 0.000 description 1
- VRZOZHNVFRLIPB-UHFFFAOYSA-N [3-chloro-5-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC(Cl)=CC(C(F)(F)F)=C1 VRZOZHNVFRLIPB-UHFFFAOYSA-N 0.000 description 1
- WXOMKINBRCKWNI-UHFFFAOYSA-N [4-(1,3,4-oxadiazol-2-yl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=NN=CO1 WXOMKINBRCKWNI-UHFFFAOYSA-N 0.000 description 1
- GDKODEQNIXNZDV-UHFFFAOYSA-N [4-(1-methylpyrazol-4-yl)phenyl]boronic acid Chemical compound Cn1cc(cn1)-c1ccc(cc1)B(O)O GDKODEQNIXNZDV-UHFFFAOYSA-N 0.000 description 1
- DWRAMTYYMNLVBD-UHFFFAOYSA-N [4-(2,2,2-trifluoroethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OCC(F)(F)F)C=C1 DWRAMTYYMNLVBD-UHFFFAOYSA-N 0.000 description 1
- UCIPLLNDFCCBAC-UHFFFAOYSA-N [4-(2-methylpropoxy)phenyl]boronic acid Chemical compound CC(C)COC1=CC=C(B(O)O)C=C1 UCIPLLNDFCCBAC-UHFFFAOYSA-N 0.000 description 1
- YZSPHVWALUJQNK-UHFFFAOYSA-N [4-(2-methylpropyl)phenyl]boronic acid Chemical compound CC(C)CC1=CC=C(B(O)O)C=C1 YZSPHVWALUJQNK-UHFFFAOYSA-N 0.000 description 1
- DXUPJOQUAAVAGV-UHFFFAOYSA-N [4-(2h-tetrazol-5-yl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=NN=NN1 DXUPJOQUAAVAGV-UHFFFAOYSA-N 0.000 description 1
- JEVVHTYCMAMSJL-UHFFFAOYSA-N [4-(diethylamino)phenyl]boronic acid Chemical compound CCN(CC)C1=CC=C(B(O)O)C=C1 JEVVHTYCMAMSJL-UHFFFAOYSA-N 0.000 description 1
- MFZNJRNTHPKCFY-UHFFFAOYSA-N [4-(difluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)F)C=C1 MFZNJRNTHPKCFY-UHFFFAOYSA-N 0.000 description 1
- BKHBDGFRIWAUKK-UHFFFAOYSA-N [4-(difluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)F)C=C1 BKHBDGFRIWAUKK-UHFFFAOYSA-N 0.000 description 1
- RIIPFHVHLXPMHQ-UHFFFAOYSA-N [4-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=C(B(O)O)C=C1 RIIPFHVHLXPMHQ-UHFFFAOYSA-N 0.000 description 1
- MGQAKEVQIPUEPM-UHFFFAOYSA-N [4-(dimethylcarbamoyl)-3-methylphenyl]boronic acid Chemical compound CN(C(=O)C1=C(C=C(C=C1)B(O)O)C)C MGQAKEVQIPUEPM-UHFFFAOYSA-N 0.000 description 1
- QJYYVSIRDJVQJW-UHFFFAOYSA-N [4-(dimethylcarbamoyl)phenyl]boronic acid Chemical compound CN(C)C(=O)C1=CC=C(B(O)O)C=C1 QJYYVSIRDJVQJW-UHFFFAOYSA-N 0.000 description 1
- VTNVZXAYRMTKON-UHFFFAOYSA-N [4-(methoxymethyl)phenyl]boronic acid Chemical compound COCC1=CC=C(B(O)O)C=C1 VTNVZXAYRMTKON-UHFFFAOYSA-N 0.000 description 1
- QPFDUULIDNELSE-UHFFFAOYSA-N [4-(morpholin-4-ylmethyl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1CN1CCOCC1 QPFDUULIDNELSE-UHFFFAOYSA-N 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 1
- OKHCKPPOCZWHRN-UHFFFAOYSA-N [4-[(2-methylpropan-2-yl)oxy]phenyl]boronic acid Chemical compound CC(C)(C)OC1=CC=C(B(O)O)C=C1 OKHCKPPOCZWHRN-UHFFFAOYSA-N 0.000 description 1
- LRWRYAVXFZBFRJ-UHFFFAOYSA-N [4-[(dimethylamino)methyl]phenyl]boronic acid Chemical compound CN(C)CC1=CC=C(B(O)O)C=C1 LRWRYAVXFZBFRJ-UHFFFAOYSA-N 0.000 description 1
- SHCPXHBLEGXHIV-UHFFFAOYSA-N [4-ethoxy-3-(trifluoromethyl)phenyl]boronic acid Chemical compound CCOC1=CC=C(B(O)O)C=C1C(F)(F)F SHCPXHBLEGXHIV-UHFFFAOYSA-N 0.000 description 1
- ZBCRZEJNAADYKG-UHFFFAOYSA-N [4-methoxy-2-(trifluoromethyl)phenyl]boronic acid Chemical compound COC1=CC=C(B(O)O)C(C(F)(F)F)=C1 ZBCRZEJNAADYKG-UHFFFAOYSA-N 0.000 description 1
- BUSMBMGODABSIN-UHFFFAOYSA-N [4-methoxy-3-(trifluoromethyl)phenyl]boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1C(F)(F)F BUSMBMGODABSIN-UHFFFAOYSA-N 0.000 description 1
- WNDRDSTVBFGULJ-UHFFFAOYSA-N [4-phenylmethoxy-3-(trifluoromethyl)phenyl]boronic acid Chemical compound FC(F)(F)C1=CC(B(O)O)=CC=C1OCC1=CC=CC=C1 WNDRDSTVBFGULJ-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- TUPZMLLDXCWVKH-UHFFFAOYSA-N pyrazolo[4,3-b]pyridin-3-one Chemical class C1=CN=C2C(=O)N=NC2=C1 TUPZMLLDXCWVKH-UHFFFAOYSA-N 0.000 description 1
- 150000005229 pyrazolopyridines Chemical class 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
吡唑并[3,4‑b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用,本发明公开了一种如式(Ⅰ)所示结构的化合物(各基团定义如说明书中所述)、或其立体异构体、或其药学上可接受的盐,以及包含其的药物组合物;还公开了如式(Ⅰ)所示结构的化合物的制备方法;此外还公开了如式(Ⅰ)所示结构的化合物作为HPK1抑制剂在制备用于治疗HPK1相关障碍或疾病的药物中的应用。
Description
技术领域
本发明涉及医药技术领域,尤其涉及一种吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用。
背景技术
HPK1调节各种免疫细胞的多样功能,并且已显示其激酶活性在T细胞受体(TCR)[Liou J.,等人,Immunity,2000.12(4):p.399-408]、B细胞受体(BCR)[Liou J.,等人,Immunity,2000.12(4):p.399-408]、转化生长因子受体(TGF-βR)[Wang,W.,等人,JBiolChem,1997.272(36):第22771-5页;Zhou,G.,等人,J Biol Chem,1999.274(19):第13133-8页]、或Gs偶联的PGE2受体(EP2和EP4)[Ikegami,R.,等人,J Immunol,2001.166(7):第4689-96页]的激活之后被诱导。HPK1的过表达以激酶依赖性的方式抑制TCR诱导的AP-1依赖性基因转录的激活,表明需要HPK1来抑制Erk MAPK途径[Liou J.,等人,Immunity,2000.12(4):第399-408页]并且这种阻断被认为是负调节TCR诱导的IL-2基因转录的抑制机制[S.Sawasdikosol.,等人,Immunol Res,2012.54:262-265]。
体外HPK1-/-T细胞具有较低的TCR激活阈值,稳健地增殖、产生增强量的Th1细胞因子,HPK1-/-小鼠经历更严重的自身免疫症状[S.Sawasdikosol.,等人,Immunol Res,2012.54:262-265]。在人体中,HPK1在银屑病性关节炎患者的外周血单核细胞或系统性红斑狼疮(SLE)患者的T细胞中下调[Batliwalla F.M.,等人,Mol Med,2005.11(1-12):第21-9页],这表明HPK1活性的减弱可能有助于患者的自身免疫。此外,HPK1还可以经由T细胞依赖性机制控制抗肿瘤免疫。在产生PGE2的Lewis肺癌肿瘤模型中,与野生型小鼠相比,肿瘤在HPK1敲除小鼠中发展得更慢[美国专利申请号2007/0087988]。HPK1缺陷型T细胞在控制肿瘤生长和转移方面比野生型T细胞更有效[Al za bi n,S.,等人,Cancer ImmunolImmunother,2010.59(3):第419-29页]。类似地,与野生型BMDC相比,来自HPK1敲除小鼠的BMDC更有效地产生T细胞应答以根除Lewis肺癌[Alzabin,S.,等人,J Immunol,2009.182(10):第6187-94页]。总之,HPK1可能是用于增强抗肿瘤免疫的良好靶标。
作为HPK1调节剂,WO 2016205942公开了苯并咪唑,WO 2018049152 A1公开了吡唑并嘧啶,WO 2018049191 A1公开了吡唑并吡啶酮,WO 2018049200A1公开了吡唑并吡啶[3,4-c],CN 112239473和CN 112243439公开了吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪。
尽管WO 2018049214A1及WO 2008124849公开了吡唑并[3,4-b]吡啶能作为HPK1调节剂,但其HPK1调节活性有待改进。
发明内容
本发明公开了一种吡唑并[3,4-b]吡啶类衍生物及其制备方法,该吡唑并[3,4-b]吡啶类衍生物可调节(例如抑制)造血祖细胞1(HPK1)活性,可用于制备治疗包括癌症在内的多种疾病。
本发明的技术方案如下:
一种如式(Ⅰ)所示结构的化合物、其立体异构体或其药学上可接受的盐;
其中:
L1是单键、亚烷基、亚环烷基、*1-O-亚烷基-**1、*1-亚烷基-O-**1、*1-NH-亚烷基-**1、*1-亚烷基-NH-**1、*1-NHC(O)-**1、*1-C(O)NH-**1、亚烯基或亚炔基,其中*1是指与Cy1附接的位置,并且**1是指与附接的位置;
Cy1是包含一个或两个独立地选自氮、氧或任选氧化的硫中的杂原子作为一个或多个环成员的5或6元杂环基,并且在所述杂环是6元环时,R1相对于附接点L1在所述杂环基的对位(或4位)处;或者Cy1是包含一或二或三个独立地选自氮、氧或任选氧化的硫中的杂原子作为一个或多个环成员的7至10元双环稠合的杂环基;
R1是卤素、-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基、杂芳基、氧代基、-CN、-NO2、-OR1a、-SO2R1a、-SO2NR1aR1b、-COR1a、-CO2R1a、-CONR1aR1b、-C(=NR1a)NR1bR1c、-NR1aR1b、-NR1aCOR1b、-NR1aCONR1bR1c、-NR1aCO2R1b、-NR1aSONR1bR1c、-NR1aSO2NR1bR1c或-NR1aSO2R1b,所述-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基或杂芳基各自任选地被至少一个取代基R1d取代;
R1a、R1b和R1c各自独立地是氢、-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基或杂芳基,所述-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基、或杂芳基各自任选地被至少一个取代基R1e取代;或者(R1a和R1b)、(R1b和R1c)或(R1c和R1a)与它们所附接的一个或多个原子一起形成3至12元环,所述环包含0、1或2个独立地选自氮、氧或任选氧化的硫中的杂原子作为一个或多个环成员,所述环任选地被至少一个取代基R1e取代;
R1d和R1e各自独立地是氢、卤素、-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基、杂芳基、氧代基、-CN、-NO2、-OR1f、-SO2R1f、-SO2NR1fR1g、-COR1f、-CO2R1f、-CONR1fR1g、-C(=NR1f)NR1gR1h、-NR1fR1g、-NR1fCOR1g、-NR1fCONR1gR1h、-NR1fCO2R1f、-NR1fSONR1fR1g、-NR1fSO2NR1gR1h或-NR1fSO2R1g,所述-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基、或杂芳基各自任选地被至少一个选自卤素、-C1-8烷基、-OR1i、-NR1iR1j、环烷基、杂环基、芳基、或杂芳基的取代基取代;
R1f、R1g、R1h、R1i、和R1j各自独立地是氢、-C1-8烷基、C1-8烷氧基-C1-8烷基-、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基或杂芳基。
优选的,所述的6元杂环基是哌啶基、四氢吡啶基或哌嗪基。
优选的,所述的7至10元双环稠合杂环基是二氢吡啶并噁嗪、二氢苯并氧氮杂卓基、异吲哚啉基、二氢异喹啉基、四氢异喹啉基、苯并氮杂卓基、苯并氧氮杂卓基或二氢苯并噁嗪。
进一步优选的,所述的7至10元双环稠合杂环基是2,3-二氢-1H-吡啶并[2,3-b][1,4]噁嗪、5-氧代-3,4-二氢苯并[f][1,4]氧氮杂卓基、1-氧代-2-甲基异吲哚啉-5-基、1-氧代-2-甲基-3,4-二氢异喹啉-6-基、2-甲基-1-氧代-1,2,3,4-四氢异喹啉-6-基、2,3,4,5-四氢-1-氧代-2-苯并氮杂卓-6-基、5-氧代-2,3,4,5-四氢-1,4-苯并氧氮杂卓-8-基或3,4-二氢-2H-1,4-苯并噁嗪-6-基。
优选的,所述的化合物选自:
本发明还提供了如式(Ⅰ)所示结构的化合物的制备方法,包括以下步骤:
本发明还提供了另一种如式(Ⅰ)所示结构的化合物的制备方法,包括以下步骤:
本发明还提供了另一种如式(Ⅰ)所示结构的化合物的制备方法,包括以下步骤:
本发明还提供了一种药物组合物,其包含治疗有效量的上述化合物、其立体异构体或其药学上可接受的盐,以及药学上可接受的赋形剂或载体。
优选的,所述的药物组合物中进一步包含化疗剂。
本发明还提供了一种如式(Ⅰ)所示结构的化合物、其立体异构体或其药学上可接受的盐作为HPK1抑制剂的在制备用于治疗HPK1相关障碍或疾病的药物中的应用。
优选的,所述的HPK1相关障碍或疾病具有升高的T细胞浸润水平的特征。
进一步的,所述的HPK1相关障碍或疾病选自结肠直肠癌、黑色素瘤、非小细胞肺癌、卵巢癌、乳腺癌、胰腺癌、血液系统恶性肿瘤和肾细胞癌。
与现有技术相比,本发明的有益效果为:
本发明首次公开了结构新型的吡唑并[3,4-b]吡啶类衍生物,其药理学活性表明对HPK1激酶的活性抑制效果明显,该类化合物或其立体异构体、或其药学上可接受的盐,以及包含其的药物组合物在靶向HPK1靶点相关疾病具有潜在应用价值。此外,本发明还公开了新型吡唑并[3,4-b]吡啶类衍生物的合成路线,其特点在于合成简单,操作便捷。
具体实施方式
实施例1:3-(3-氟-4-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物1)
步骤1:5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物1-1)
向5-溴-1H-吡唑并[3,4-b]吡啶(1.97g,1.0eq.)和(4-(4-甲基哌嗪-1-基)苯基)硼酸(2.2g,1.0eq.)在二氧六环(100mL)和水(50mL)中的混合物中添加K2CO3(4.14g,3.0eq.)和Pd(dppf)Cl2(731mg,0.1eq.)。将反应混合物在氮气下在100℃搅拌4h。将混合物冷却至室温并减压浓缩,将残余物通过硅胶柱色谱法(二氯甲烷:MeOH=20:1)纯化得化合物1-1(2.1g,85%)。1H NMR(400MHz,DMSO-d6)δ13.65(s,1H),8.79(d,J=2.2Hz,1H),8.36(d,J=2.1Hz,1H),8.16(s,1H),7.60(d,J=8.8Hz,2H),7.05(d,J=8.8Hz,2H),3.29–3.00(m,4H),2.50–2.42(m,4H),2.24(s,3H)。LC-MS(M+H)+=294.14,Rt=7.757min。
步骤2:3-碘-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物1-2)
向5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物1-1,1.5g,1.0eq.)、氢氧化钠溶液(0.82g,4.0eq.)和碘单质(2.6g,2.0eq.)在二氧六环溶剂中回流24h,将混合物冷却至室温并减压浓缩,将残余物通过硅胶柱色谱法(二氯甲烷:MeOH=20:1)纯化得化合物1-2(1.5mg,80%)。1H NMR(400MHz,DMSO)δ8.77(s,1H),7.90(s,1H),7.64(d,J=6.9Hz,2H),7.05(d,J=6.8Hz,2H),3.20(s,4H),2.45(t,J=16.0Hz,4H),2.23(s,3H).。LC-MS(M+H)+=420.02,Rt=9.119min。
步骤3:3-(3-氟-4-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物1)
向(3-氟-4-甲氧基苯基)硼酸(48.7mg,1.2eq.)和3-碘-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物1-2,100mg,1eq.)在二氧六环(50mL)和水(4mL)中的混合物中添加K2CO3(99.5mg,3.0eq)和Pd(dppf)Cl2(17.4mg,0.1eq)。将反应混合物在氮气下在100℃搅拌4h。将混合物冷却至室温并减压浓缩,将残余物通过硅胶柱色谱法(二氯甲烷:MeOH=20:1)纯化得化合物1(28mg,30%)。1H NMR(400MHz,DMSO-d6)DMSO)δ13.81(s,1H),8.83(s,1H),8.59(s,1H),7.90(t,J=9.5Hz,2H),7.69(d,J=8.3Hz,2H),7.32(t,J=8.8Hz,1H),7.06(d,J=8.4Hz,2H),3.92(s,3H),3.27–3.12(m,4H),2.49–2.41(m,4H),2.23(s,3H)。LC-MS(M+H)+=418.17,Rt=9.939min。
实施例2:3-(4-异丙氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物2)
以与在实施例1步骤3中描述的方式类似的方式由(4-异丙氧基苯基)硼酸和化合物1-2(100mg,1.0eq.)制备化合物2(60mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.68(s,1H),8.81(d,J=1.9Hz,1H),8.55(d,J=1.7Hz,1H),8.01(d,J=8.7Hz,2H),7.68(d,J=8.7Hz,2H),7.06(t,J=8.2Hz,4H),4.69(dt,J=12.0,6.0Hz,1H),3.42-3.32(m,4H),3.25–3.10(m,4H),2.23(s,3H),1.31(d,J=6.0Hz,6H)。LC-MS(M+H)+=428.22,Rt=10.793min。
实施例3:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(3,4,5-三氟苯基)-1H-吡唑并[3,4-b]吡啶(化合物3)
以与在实施例1步骤3中描述的方式类似的方式由(3,4,5-三氟苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物3(25mg,30%)。1H NMR(400MHz,DMSO-d6)δ13.94(s,1H),8.82(d,J=1.9Hz,,1H),8.63(d,J=1.6Hz,,1H),8.12–7.85(m,2H),7.69(d,J=8.0Hz,2H),7.04(d,J=8.0Hz,2H),3.19-3.24(m,4H),2.46-2.53(m,4H),2.24(s,3H)。LC-MS(M+H)+=424.14,Rt=11.088min。
实施例4:3-(2,3-二氟苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物4)
以与在实施例1步骤3中描述的方式类似的方式由(2,3-二氟苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物4(18mg,25%)。1H NMR(400MHz,DMSO-d6)δ14.13(s,1H),8.88(d,J=1.9Hz,1H),8.38(d,J=2.0Hz,1H),7.75(t,J=7.0Hz,1H),7.64(d,J=8.7Hz,2H),7.58–7.52(m,1H),7.45–7.30(m,1H),7.05(d,J=8.7Hz,2H),3.27–3.15(m,4H),2.50–2.44(m,4H),2.24(s,3H)。LC-MS(M+H)+=406.17,Rt=10.103min。
实施例5:3-(2,3-二氟-4-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物5)
以与在实施例1步骤3中描述的方式类似的方式由(2,3-二氟-4-甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物5(35mg,40%)。1H NMR(400MHz,DMSO-d6)δ14.04(s,1H),8.88(d,J=1.9Hz,1H),8.37(d,J=1.8Hz,1H),7.71(d,J=7.6Hz,1H),7.66(d,J=8.3Hz,2H),7.23(t,J=8.1Hz,1H),7.09(d,J=8.2Hz,2H),4.00(s,3H),3.15-3.31(m,4H),2.15-2.38(m,4H),2.27(s,3H).。LC-MS(M+H)+=436.18,Rt=10.327min。
实施例6:3-(6-甲氧基吡啶-3-基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物6)
步骤1:5-溴-3-(6-甲氧基吡啶-3-基)-1H-吡唑并[3,4-b]吡啶(化合物6-1)
向5-溴-3-碘-1H-吡唑并[3,4-b]吡啶(0.323g,1.0eq.)和(6-甲氧基吡啶-3-基)硼酸(0.153g,1.0eq.)在二氧六环(15mL)和水(3mL)中的混合物中添加K2CO3(0.408g,3.0eq.)和Pd(dppf)Cl2(73mg,0.1eq.)。将反应混合物在氮气下在100℃搅拌4h。将混合物冷却至室温并减压浓缩,将残余物通过硅胶柱色谱法(石油醚:乙酸乙酯=3:1)纯化得化合物6-1(180mg,60%)。1H NMR(400MHz,DMSO-d6)δ14.06(s,1H),8.84(dd,J=4.0,2.3Hz,2H),8.65(d,J=2.1Hz,1H),8.33(dd,J=8.6,2.5Hz,1H),6.97(d,J=8.6Hz,1H),3.94(s,3H);LC-MS(M+H)+=304.93,Rt=14.330min。
步骤2:3-(6-甲氧基吡啶-3-基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物6)
向化合物6-1(0.100g,1.0eq.)和(4-(4-甲基哌嗪-1-基)苯基)硼酸(94mg,1.3eq.)在二氧六环(10mL)和水(2mL)中的混合物中添加K2CO3(0.136g,3.0eq.)和Pd(dppf)Cl2(24mg,0.1eq.)。将反应混合物在氮气下在100℃搅拌4h。将混合物冷却至室温并减压浓缩,将残余物通过硅胶柱色谱法(二氯甲烷:甲醇=15:1)纯化得化合物6(80mg,60%)。1HNMR(400MHz,DMSO-d6)δ13.85(s,1H),8.92(d,J=2.1Hz,1H),8.84(d,J=1.9Hz,1H),8.61(d,J=1.9Hz,1H),8.39(dd,J=8.6,2.4Hz,1H),7.72(d,J=8.7Hz,2H),7.05(d,J=8.8Hz,2H),6.99(d,J=8.6Hz,1H),3.95(s,3H),3.25–3.14(m,4H),2.50–2.43(m,4H),2.23(s,3H)。LC-MS(M+H)+=401.20,Rt=9.879min。
实施例7:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(吡啶-3-基)-1H-吡唑并[3,4-b]吡啶(化合物7)
以与在实施例1步骤3中描述的方式类似的方式由吡啶-3-基硼酸和化合物1-2(100mg,1.0eq)制备化合物7(20mg,25%)。1H NMR(400MHz,DMSO-d6)δ13.75(s,1H),9.02(m,2H),8.84(m,2H),8.61(d,J=1.9Hz,1H),8.09(s,1H),7.71(d,J=8.7Hz,1H),7.02(d,J=8.8Hz,2H),6.94(d,J=8.6Hz,1H),3.21–3.12(m,4H),2.53–2.45(m,4H),2.22(s,3H)。LC-MS(M+H)+=371.15,Rt=8.446min。
实施例8:5-(4-(4-甲基哌嗪-1-基)苯基)-3-苯基)-1H-吡唑并[3,4-b]吡啶(化合物8)
以与在实施例1步骤3中描述的方式类似的方式由苯硼酸和化合物1-2(100mg,1.0eq)制备化合物8(50mg,60%)。1H NMR(400MHz,DMSO-d6)δ13.79(s,1H),8.84(s,1H),8.60(s,1H),8.12(d,J=7.1Hz,2H),7.69(d,J=7.7Hz,2H),7.57(t,J=6.7Hz,2H),7.45(t,J=6.5Hz,1H),7.06(d,J=7.7Hz,2H),3.26–3.10(m,4H),2.53–2.41(m,4H),2.25(s,3H)。LC-MS(M+H)+=370.19,Rt=10.096min。
实施例9:4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苄腈(化合物9)
以与在实施例1步骤3中描述的方式类似的方式由(4-氰基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物9(17mg,20%)。1H NMR(400MHz,DMSO-d6)δ14.14(s,1H),8.87(d,J=2.0Hz,1H),8.67(d,J=2.0Hz,1H),8.33(d,J=8.4Hz,2H),7.97(d,J=8.4Hz,2H),7.70(d,J=8.7Hz,2H),7.06(d,J=8.8Hz,2H),3.31–3.02(m,4H),2.52–2.35(m,4H),2.24(s,3H)。LC-MS(M+H)+=395.16,Rt=9.243min。
实施例10:3-(3-(苄氧基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物10)
以与在实施例1步骤3中描述的方式类似的方式由(3-(苄氧基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物10(25mg,30%)。1H NMR(400MHz,DMSO-d6)δ13.88(s,1H),8.82(d,J=2.0Hz,1H),8.50(d,J=2.0Hz,1H),7.70(d,J=7.7Hz,1H),7.65(dd,J=5.6,3.0Hz,3H),7.49(dd,J=15.6,7.6Hz,3H),7.39(t,J=7.3Hz,2H),7.36–7.29(m,1H),7.10(dd,J=8.2,2.0Hz,1H),7.05(d,J=8.8Hz,2H),5.24(s,2H),3.19–3.11(m,4H),2.50–2.37(m,4H),2.22(s,3H)。LC-MS(M+H)+=476.27,Rt=11.698min。
实施例11:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(甲硫基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物11)
以与在实施例1步骤3中描述的方式类似的方式由(4-(甲硫基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物11(18mg,30%)。1H NMR(400MHz,DMSO)δ13.81(s,1H),8.82(d,J=6.2Hz,1H),8.59(d,J=1.8Hz,1H),8.06(d,J=8.4Hz,2H),7.69(d,J=8.7Hz,2H),7.42(d,J=8.4Hz,2H),7.06(d,J=8.8Hz,2H),3.27–3.11(m,4H),2.55(s,3H),2.49–2.43(m,4H),2.23(s,3H).。LC-MS(M+H)+=416.17,Rt=10.802min。
实施例12:3-(3-氯-5-(三氟甲基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物12)
以与在实施例1步骤3中描述的方式类似的方式由(3-氯-5-(三氟甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物12(25mg,40%)。1H NMR(400MHz,DMSO-d6)δ14.14(s,1H),8.85(d,J=1.8Hz,1H),8.62(d,J=1.8Hz,1H),8.41(s,1H),8.28(s,1H),7.90(s,1H),7.69(d,J=8.7Hz,2H),7.07(d,J=8.7Hz,2H),3.26–3.15(m,4H),2.50–2.40(m,4H),2.24(s,3H)。LC-MS(M+H)+=472.12,Rt=12.173min。
实施例13:3-(5-氯-2-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物13)
以与在实施例1步骤3中描述的方式类似的方式由(5-氯-2-甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物13(20mg,35%)。1H NMR(400MHz,DMSO-d6)δ13.78(s,1H),8.79(d,J=2.0Hz,1H),8.23(d,J=2.1Hz,1H),7.66(d,J=2.7Hz,1H),7.58(d,J=8.7Hz,2H),7.47(dd,J=8.8,2.7Hz,1H),7.24(d,J=8.9Hz,1H),7.02(d,J=8.7Hz,2H),3.87(s,3H),3.22–3.17(m,4H),2.49–2.44(m,4H),2.23(s,3H).。LC-MS(M+H)+=434.14,Rt=10.658min。
实施例14:N-(3-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯基)乙酰胺(化合物14)
以与在实施例1步骤3中描述的方式类似的方式由(3-乙酰氨基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物14(22mg,35%)。1H NMR(400MHz,DMSO-d6)δ13.79(s,1H),10.04(s,1H),8.83(d,J=2.0Hz,1H),8.58(d,J=2.1Hz,1H),8.38(s,1H),7.78(d,J=7.8Hz,1H),7.67(dd,J=12.6,9.2Hz,3H),7.47(t,J=7.9Hz,1H),7.05(d,J=8.8Hz,2H),3.23–3.17(m,4H),2.50–2.43(m,4H),2.24(s,3H),2.12(s,3H)。LC-MS(M+H)+=427.22,Rt=9.321min。
实施例15:3-(2-氯-4-甲基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物15)
以与在实施例1步骤3中描述的方式类似的方式由(2-氯苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物15(30mg,45%)。1H NMR(400MHz,DMSO-d6)δ13.94(s,1H),8.86(d,J=2.1Hz,1H),8.17(d,J=2.1Hz,1H),7.66–7.57(m,3H),7.52(s,1H),7.34(dd,J=7.8,0.8Hz,1H),7.06(d,J=8.9Hz,2H),3.26–3.17(m,4H),2.52–2.46(m,4H),2.44(s,3H),2.25(s,3H).。LC-MS(M+H)+=418.13,Rt=10.646min。
实施例16:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(萘-2-基)-1H-吡唑并[3,4-b]吡啶(化合物16)
以与在实施例1步骤3中描述的方式类似的方式由萘-2-基硼酸和化合物1-2(100mg,1.0eq)制备化合物16(25mg,45%)。1H NMR(400MHz,DMSO)δ13.95(s,1H),8.86(d,J=1.9Hz,1H),8.80(d,J=2.0Hz,1H),8.70(s,1H),8.28(dd,J=8.6,1.6Hz,1H),8.23–8.15(m,1H),8.07(d,J=8.7Hz,1H),7.98(d,J=7.1Hz,1H),7.73(d,J=8.7Hz,2H),7.62–7.52(m,2H),7.07(d,J=8.8Hz,2H),3.24–3.16(m,4H),2.50–2.44(m,4H),2.23(s,3H).。LC-MS(M+H)+=420.17,Rt=11.240min。
实施例17:N,N-二甲基-4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯胺(化合物17)
以与在实施例1步骤3中描述的方式类似的方式由(4-(二甲氨基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物17(55mg,70%)。1H NMR(400MHz,CDCl3)δ12.43(s,1H),8.84(d,J=1.8Hz,1H),8.45(d,J=1.9Hz,1H),7.91(d,J=8.8Hz,2H),7.55(d,J=8.6Hz,2H),7.05(d,J=8.7Hz,2H),6.87(d,J=8.8Hz,2H),3.35–3.27(m,4H),3.04(s,6H),2.67–2.61(m,4H),2.39(s,3H).。LC-MS(M+H)+=413.21,Rt=10.231min。
实施例18:3-(4-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物18)
以与在实施例1步骤3中描述的方式类似的方式由(4-甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物18(48mg,60%)。1H NMR(400MHz,DMSO-d6)δ13.69(s,1H),8.81(d,J=1.9Hz,1H),8.55(d,J=1.9Hz,1H),8.04(d,J=8.7Hz,2H),7.68(d,J=8.7Hz,2H),7.11(d,J=8.7Hz,2H),7.05(d,J=8.8Hz,2H),3.84(s,3H),3.28–3.15(m,4H),2.49–2.42(m,4H),2.23(s,3H)。LC-MS(M+H)+=400.30,Rt=9.942min。
实施例19:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(2-(甲硫基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物19)
以与在实施例1步骤3中描述的方式类似的方式由(2-(甲硫基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物19(15mg,20%)。1H NMR(400MHz,DMSO-d6)δ13.90(s,1H),8.85(d,J=1.9Hz,1H),8.18(d,J=1.8Hz,1H),7.61(d,J=8.7Hz,3H),7.50(q,J=8.0Hz,2H),7.38–7.29(m,1H),7.04(d,J=8.7Hz,2H),3.25–3.12(m,4H),2.51–2.44(m,4H),2.42(s,3H),2.24(s,3H)。LC-MS(M+H)+=416.21,Rt=9.880min。
实施例20:3-(3-异丙氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物20)
以与在实施例1步骤3中描述的方式类似的方式由(3-异丙氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物20(25mg,35%)。1H NMR(400MHz,DMSO-d6)1H NMR(400MHz,DMSO)δ13.91(s,1H),8.85(s,1H),8.54(s,1H),7.67(t,J=7.8Hz,3H),7.57(s,1H),7.47(t,J=7.6Hz,1H),7.02(t,J=9.1Hz,3H),5.08–4.48(m,1H),3.28–3.10(m,4H),2.51–2.38(m,4H),2.22(s,3H),1.33(d,J=5.4Hz,6H).。LC-MS(M+H)+=428.25,Rt=10.928min。
实施例21:3-(4-(甲氧基甲基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物21)
以与在实施例1步骤3中描述的方式类似的方式由(4-(甲氧基甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物21(45mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.80(s,1H),8.83(d,J=1.5Hz,1H),8.58(d,J=1.5Hz,1H),8.10(d,J=8.0Hz,2H),7.66(d,J=8.6Hz,2H),7.49(d,J=8.0Hz,2H),7.03(d,J=8.6Hz,2H),4.49(s,2H),3.35(s,3H),3.26–3.18(m,4H),2.55–2.50(m,4H),2.28(s,3H)。LC-MS(M+H)+=414.21,Rt=9.915min。
实施例22:3-(3,4-二甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物22)
以与在实施例1步骤3中描述的方式类似的方式由(3,4-二甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物22(38mg,50%)。1H NMR(400MHz,CDCl3)δ12.89(s,1H),8.86(d,J=2.0Hz,1H),8.43(d,J=2.0Hz,1H),7.59(d,J=1.9Hz,1H),7.54(t,J=5.5Hz,3H),7.07(s,1H),7.06–6.99(m,2H),4.01(s,3H),3.97(s,3H),3.39–3.22(m,4H),2.73–2.58(m,4H),2.40(s,3H).。LC-MS(M+H)+=430.06,Rt=9.782min。δ11.87(s,1H),8.54(d,J=2.0Hz,1H),8.35(d,J=1.9Hz,1H),7.85(d,J=2.2Hz,1H),7.63(d,J=8.7Hz,2H),7.38–7.28(m,2H),7.08(dd,J=8.4,6.0Hz,3H),3.90(s,3H),3.83(s,3H),3.24–3.15(m,4H),2.53–2.45(m,4H),2.27(s,3H)
实施例23:3-(4-乙基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物23)
以与在实施例1步骤3中描述的方式类似的方式由(4-乙基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物23(25mg,45%)。1H NMR(400MHz,DMSO-d6)δ13.82(s,1H),8.84(s,1H),8.58(s,1H),8.03(d,J=7.3Hz,2H),7.65(d,J=7.6Hz,2H),7.37(d,J=7.1Hz,2H),7.01(d,J=7.5Hz,2H),3.23–3.08(m,4H),2.72–2.60(m,2H),2.49–2.37(m,4H),2.21(s,3H),1.22(t,J=7.0Hz,3H)。LC-MS(M+H)+=398.20,Rt=11.205min。
实施例24:3-(3-氯-4-氟苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物24)
以与在实施例1步骤3中描述的方式类似的方式由(3-氯-4-氟苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物24(17mg,20%)。1H NMR(400MHz,CDCl3)δ12.77(s,1H),8.86(d,J=1.8Hz,1H),8.36(d,J=1.9Hz,1H),8.05(dd,J=7.0,2.0Hz,1H),7.87(ddd,J=8.4,4.5,2.1Hz,1H),7.54(d,J=8.7Hz,2H),7.29(dd,J=14.7,6.0Hz,2H),7.06(d,J=8.7Hz,2H),3.37–3.29(m,4H),2.70–2.61(m,4H),2.41(s,3H).。LC-MS(M+H)+=422.10,Rt=11.178min。
实施例25:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-戊基苯基)-1H-吡唑并[3,4-b]吡啶(化合物25)
以与在实施例1步骤3中描述的方式类似的方式由(4-戊基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物25(20mg,35%)。1H NMR(400MHz,(400MHz,CDCl3)δ12.80(s,1H),8.87(d,J=2.0Hz,1H),8.46(d,J=2.0Hz,1H),7.93(d,J=8.1Hz,2H),7.56(d,J=8.7Hz,2H),7.35(d,J=8.1Hz,2H),7.06(d,J=8.8Hz,2H),3.35–3.27(m,4H),2.74–2.66(m,2H),2.66–2.60(m,4H),2.40(s,3H),1.74–1.62(m,2H),1.36(td,J=7.6,3.6Hz,4H),0.91(t,J=6.9Hz,3H).。LC-MS(M+H)+=440.26,Rt=12.614min。
实施例26:3-(3-异丙基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物26)
以与在实施例1步骤3中描述的方式类似的方式由(3-异丙基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物26(18mg,25%)。1H NMR(400MHz,DMSO-d6)δ13.76(s,1H),8.83(s,1H),8.54(s,1H),7.91(d,J=8.4Hz,2H),7.65(d,J=8.4Hz,2H),7.48(t,J=7.5Hz,1H),7.32(d,J=7.5Hz,1H),7.04(d,J=8.5Hz,2H),3.23–3.15(m,J=4.3Hz,4H),3.04(dt,J=13.6,6.8Hz,1H),2.51–2.41(m,4H),2.24(s,3H),1.30(d,J=6.8Hz,6H)。LC-MS(M+H)+=412.21,Rt=11.556min。
实施例27:3-(2-乙氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物27)
以与在实施例1步骤3中描述的方式类似的方式由(2-乙氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物27(22mg,35%)。1H NMR(400MHz,DMSO-d6)δ13.66(s,1H),8.80(d,J=1.8Hz,1H),8.31(d,J=1.8Hz,1H),7.68(d,J=6.5Hz,1H),7.58(d,J=8.6Hz,2H),7.42(t,J=7.2Hz,1H),7.18(d,J=8.2Hz,1H),7.08(t,J=7.4Hz,1H),7.01(d,J=8.6Hz,2H),4.14(q,J=6.9Hz,2H),3.21–3.14(m,4H),2.49–2.40(m,4H),2.22(s,3H),1.19(t,J=6.9Hz,3H)。LC-MS(M+H)+=414.21,Rt=10.273min。
实施例28:3N,N-二甲基-4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯甲酰胺(化合物28)
以与在实施例1步骤3中描述的方式类似的方式由(4-(二甲基氨基甲酰基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物28(60mg,80%)。1H NMR(400MHz,CDCl3)δ13.03(s,1H),8.87(d,J=1.9Hz,1H),8.44(d,J=2.0Hz,1H),8.05(d,J=8.2Hz,2H),7.60(d,J=8.3Hz,2H),7.55(d,J=8.7Hz,2H),7.06(d,J=8.7Hz,2H),3.40–3.25(m,4H),3.06(s,6H),2.72–2.62(m,4H),2.40(s,3H).。LC-MS(M+H)+=441.23,Rt=9.353min。
实施例29:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(对甲苯基)-1H-吡唑并[3,4-b]吡啶(化合物29)
以与在实施例1步骤3中描述的方式类似的方式由对甲苯基硼酸和化合物1-2(100mg,1.0eq)制备化合物29(35mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.76(s,1H),8.83(s,1H),8.56(s,1H),8.01(d,J=7.3Hz,2H),7.65(d,J=7.9Hz,2H),7.35(d,J=7.3Hz,2H),7.01(d,J=7.8Hz,2H),3.21–3.12(m,4H),2.49–2.42(m,4H),2.38(s,3H),2.23(s,3H)。LC-MS(M+H)+=384.24,Rt=10.829min。
实施例30:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-苯氧基苯基)-1H-吡唑并[3,4-b]吡啶(化合物30)
以与在实施例1步骤3中描述的方式类似的方式由(4-苯氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物30(25mg,45%)。1H NMR(400MHz,DMSO-d6)δ13.80(s,1H),8.86(s,1H),8.60(s,1H),8.15(d,J=6.8Hz,2H),7.67(d,J=6.6Hz,2H),7.49–7.40(m,2H),7.23–7.10(m,5H),7.02(d,J=6.8Hz,2H),3.22–3.14(m,4H),2.50–2.42(m,4H),2.25(s,3H。LC-MS(M+H)+=462.24,Rt=11.795min。
实施例31:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(三甲基甲硅烷基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物31)
以与在实施例1步骤3中描述的方式类似的方式由(4-(三甲基甲硅烷基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物31(12mg,20%)。1H NMR(400MHz,DMSO-d6)δ13.86(s,1H),8.84(d,J=1.6Hz,1H),8.61(d,J=1.5Hz,1H),8.09(d,J=7.8Hz,2H),7.73–7.65(m,4H),7.05(d,J=8.6Hz,2H),3.31–3.07(m,4H),2.51–2.38(m,4H),2.23(s,3H),0.30(s,9H)。LC-MS(M+H)+=442.24,Rt=12.495min。
实施例32:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(3-(三氟甲氧基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物32)
以与在实施例1步骤3中描述的方式类似的方式由(3-(三氟甲氧基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物32(22mg,45%)。1H NMR(400MHz,DMSO-d6)δ14.12(s,1H),8.88(s,1H),8.64(s,1H),8.21(d,J=7.6Hz,1H),8.02(s,1H),7.71(dd,J=14.2,8.1Hz,3H),7.44(d,J=7.8Hz,1H),7.11(d,J=8.3Hz,2H),3.42–3.27(m,4H),2.95–2.76(m,4H),2.51(s,3H)。LC-MS(M+H)+=454.20,Rt=11.419min。
实施例33:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(3,4,5-三甲氧基苯基)-1H-吡唑并[3,4-b]吡啶(化合物33)
以与在实施例1步骤3中描述的方式类似的方式由(3,4,5-三甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物33(25mg,30%)。1H NMR(400MHz,CDCl3)δ13.01(s,1H),8.88(d,J=1.9Hz,1H),8.41(d,J=2.0Hz,1H),7.54(d,J=8.7Hz,2H),7.21(s,2H),7.06(d,J=8.8Hz,2H),3.97(s,6H),3.94(s,3H),3.39–3.26(m,4H),2.70–2.60(m,4H),2.40(s,3H).。LC-MS(M+H)+=460.26,Rt=9.945min。
实施例34:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-丙基苯基)-1H-吡唑并[3,4-b]吡啶(化合物34)
以与在实施例1步骤3中描述的方式类似的方式由(4-丙基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物34(35mg,55%)。1H NMR(400MHz,DMSO-d6)δ13.71(s,1H),8.84(s,1H),8.57(s,1H),8.02(d,J=7.1Hz,2H),7.68(d,J=7.6Hz,2H),7.37(d,J=7.0Hz,2H),7.05(d,J=7.6Hz,2H),3.24–3.19(m,4H),2.64(t,J=6.3Hz,2H),2.51–2.45(m,4H),2.25(s,3H),1.67(dd,J=13.2,6.3Hz,2H),0.95(t,J=6.5Hz,3H)。LC-MS(M+H)+=412.29,Rt=11.829min。
实施例35:3-(4-(叔丁基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物35)
以与在实施例1步骤3中描述的方式类似的方式由(4-(叔丁基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物35(25mg,45%)。1H NMR(400MHz,DMSO-d6)δ13.70(s,1H),8.85(s,1H),8.59(s,1H),8.04(d,J=8.2Hz,2H),7.71(d,J=8.5Hz,2H),7.60(d,J=8.2Hz,2H),7.09(d,J=8.6Hz,2H),3.25(d,J=4.3Hz,4H),2.52(s,4H),2.28(s,3H),1.39(s,9H).。LC-MS(M+H)+=426.26,Rt=12.005min。
实施例36:4-(4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯基)吗啉(化合物36)
以与在实施例1步骤3中描述的方式类似的方式由(4-吗啉代苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物36(25mg,55%)。1H NMR(400MHz,DMSO)δ13.67(s,1H),8.80(d,J=1.1Hz,1H),8.54(d,J=1.0Hz,1H),7.97(d,J=8.5Hz,2H),7.68(d,J=8.5Hz,2H),7.08(dd,J=13.7,8.7Hz,4H),3.77(d,J=4.2Hz,4H),3.26–3.16(m,8H),2.52(m,4H),2.28(s,3H).。LC-MS(M+H)+=455.27,Rt=10.012min。
实施例37:3-([1,1'-联苯]-4-基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物37)
以与在实施例1步骤3中描述的方式类似的方式由[1,1'-联苯]-4-基硼酸和化合物1-2(100mg,1.0eq)制备化合物37(15mg,30%)。1H NMR(400MHz,DMSO-d6)δ13.82(s,1H),8.84(s,1H),8.62(s,1H),8.21(d,J=6.1Hz,2H),7.84(d,J=6.3Hz,2H),7.74(d,J=5.4Hz,2H),7.67(d,J=6.4Hz,2H),7.49(s,2H),7.41–7.31(m,1H),7.04(d,J=6.2Hz,2H),3.26–3.11(m,4H),2.50–2.35(m,4H),2.23(s,3H)。LC-MS(M+H)+=446.22,Rt=11.901min。
实施例38:3-(2,3-二氢苯并[b][1,4]二恶英-6-基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物38)
以与在实施例1步骤3中描述的方式类似的方式由(2,3-二氢苯并[b][1,4]二恶英-6-基)硼酸和化合物1-2(100mg,1.0eq)制备化合物38(45mg,60%)。1H NMR(400MHz,DMSO)δ13.77(s,1H),8.81(d,J=2.0Hz,1H),8.51(d,J=1.9Hz,1H),7.70(d,J=8.7Hz,2H),7.58(dd,J=8.4,2.0Hz,1H),7.52(d,J=2.0Hz,1H),7.09(d,J=8.8Hz,2H),7.02(d,J=8.4Hz,1H),4.32(s,4H),2.53–2.50(m,8H),2.45(s,3H).。LC-MS(M+H)+=428.20,Rt=10.085min。
实施例39:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-乙烯基苯基)-1H-吡唑并[3,4-b]吡啶(化合物39)
以与在实施例1步骤3中描述的方式类似的方式由(4-乙烯基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物39(16mg,25%)。1H NMR(400MHz,DMSO-d6)δ13.88(s,1H),8.86(d,J=2.1Hz,1H),8.64(d,J=1.9Hz,1H),8.12(d,J=8.3Hz,2H),7.73(d,J=8.7Hz,2H),7.68(t,J=7.7Hz,2H),7.10(d,J=8.7Hz,2H),6.85(dd,J=17.6,10.9Hz,1H),5.94(d,J=17.7Hz,1H),5.36(d,J=11.2Hz,1H),3.29–3.24(m,4H),2.66–2.57(m,4H),2.33(s,3H)。LC-MS(M+H)+=396.20,Rt=11.077min。
实施例40:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(三氟甲氧基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物40)
以与在实施例1步骤3中描述的方式类似的方式由(4-(三氟甲氧基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物40(35mg,50%)。1H NMR(400MHz,DMSO-d6)δ14.04(s,1H),8.86(d,J=2.0Hz,1H),8.65(d,J=2.0Hz,1H),8.26(d,J=8.8Hz,2H),7.72(d,J=8.8Hz,2H),7.53(d,J=8.1Hz,2H),7.08(d,J=8.8Hz,2H),3.32–3.24(m,4H),2.70–2.56(m,4H),2.34(s,3H。LC-MS(M+H)+=454.16,Rt=11.040min。
实施例41:3-(4-(1-甲基-1H-吡唑-4-基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物41)
以与在实施例1步骤3中描述的方式类似的方式由(4-(1-甲基-1H-吡唑-4-基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物41(30mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.46(s,1H),8.81(s,1H),8.53(d,J=18.7Hz,2H),8.12(s,1H),7.67(d,J=7.7Hz,2H),7.02(d,J=7.6Hz,2H),3.98(s,3H),3.24–3.13(m,4H),2.50–2.40(m,4H),2.23(s,3H)。LC-MS(M+H)+=374.19,Rt=8.918min。
实施例42:3-([1,1'-联苯基]-3-基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物42)
以与在实施例1步骤3中描述的方式类似的方式由[1,1'-联苯]-3-基硼酸和化合物1-2(100mg,1.0eq)制备化合物42(15mg,35%)。1H NMR(400MHz,DMSO-d6)δ13.93(s,1H),8.84(d,J=1.5Hz,1H),8.59(d,J=1.3Hz,1H),8.26(s,1H),8.10(d,J=7.4Hz,1H),7.77(d,J=7.4Hz,2H),7.75–7.60(m,4H),7.51(t,J=7.5Hz,2H),7.41(t,J=7.2Hz,1H),7.07(d,J=8.6Hz,2H),3.26–3.16(m,4H),2.65–2.52(m,4H),2.30(s,3H)。LC-MS(M+H)+=446.22,Rt=11.818min。
实施例43:3-(4-异丁基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物43)
以与在实施例1步骤3中描述的方式类似的方式由(4-异丁基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物43(30mg,45%)。1H NMR(400MHz,DMSO-d6)δ13.78(s,1H),8.82(d,J=2.0Hz,1H),8.58(d,J=1.8Hz,1H),8.00(d,J=8.1Hz,2H),7.69(d,J=8.7Hz,2H),7.32(d,J=8.1Hz,2H),7.07(d,J=8.7Hz,2H),3.27–3.15(m,4H),2.51–2.50(m,6H),2.25(s,3H),1.90(dt,J=16.9,6.6Hz,1H),0.92(d,J=6.6Hz,6H)。LC-MS(M+H)+=426.26,Rt=12.161min。
实施例44:3-(4-异丁氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物44)
以与在实施例1步骤3中描述的方式类似的方式由(4-异丁氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物44(35mg,55%)。1H NMR(400MHz,DMSO-d6)δ13.68(s,1H),8.79(d,J=28.0Hz,1H),8.55(s,1H),8.02(d,J=8.2Hz,2H),7.69(d,J=8.3Hz,2H),7.12(d,J=8.7Hz,2H),7.11–7.01(m,2H),3.86(d,J=6.3Hz,2H),3.30–3.22(m,4H),2.72–2.55(m,4H),2.34(s,3H),2.09(dt,J=12.8,6.3Hz,1H),1.04(d,J=6.5Hz,6H)。LC-MS(M+H)+=442.27,Rt=11.873min。
实施例45:3-(4-乙氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物45)
以与在实施例1步骤3中描述的方式类似的方式由(4-乙氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物45(36mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.65(s,1H),8.80(s,1H),8.53(s,1H),8.00(d,J=8.1Hz,2H),7.67(d,J=8.1Hz,2H),7.13–6.99(m,4H),4.11(dd,J=13.3,6.5Hz,2H),3.36–3.29(m,4H),2.79–2.67(m,4H),2.41(s,3H),1.37(t,J=6.7Hz,3H)。LC-MS(M+H)+=414.19,Rt=10.746min。
实施例46:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(三氟甲基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物46)
以与在实施例1步骤3中描述的方式类似的方式由(4-(三氟甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物46(23mg,40%)。1H NMR(400MHz,DMSO-d6)δ14.07(s,1H),8.87(d,J=2.0Hz,1H),8.67(d,J=2.0Hz,1H),8.35(d,J=8.1Hz,2H),7.88(d,J=8.3Hz,2H),7.71(d,J=8.7Hz,2H),7.07(d,J=8.8Hz,2H),3.26–3.14(m,4H),2.50–2.42(m,J=4.9Hz,4H),2.24(s,3H)。LC-MS(M+H)+=438.18,Rt=11.374min。
实施例47:3-(2-氟-6-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物47)
以与在实施例1步骤3中描述的方式类似的方式由(2-氟-6-甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物47(17mg,25%)。1H NMR(400MHz,DMSO-d6)δ13.85(s,1H),8.82(d,J=0.6Hz,1H),8.02(s,1H),7.59(d,J=8.4Hz,2H),7.51(dd,J=15.3,8.0Hz,1H),7.17–6.85(m,4H),3.78(s,3H),3.25–3.10(m,4H),2.50–2.37(m,4H),2.22(s,3H)。LC-MS(M+H)+=418.21,Rt=9.672min。
实施例48:3-(4-乙氧基-3-(三氟甲基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物48)
以与在实施例1步骤3中描述的方式类似的方式由(4-乙氧基-3-(三氟甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物48(28mg,45%)。1H NMR(400MHz,DMSO-d6)δ13.86(s,1H),8.84(s,1H),8.56(s,1H),8.36(d,J=8.0Hz,1H),8.21(s,1H),7.67(d,J=8.3Hz,2H),7.40(d,J=8.5Hz,1H),7.06(d,J=8.4Hz,2H),4.26(dd,J=13.4,6.5Hz,2H),3.26–2.98(m,4H),2.50–2.37(m,4H),2.24(s,3H),1.66–1.27(m,J=6.8Hz,3H).。LC-MS(M+H)+=482.24,Rt=11.595min。
实施例49:3-(4-(二氟甲基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物49)
以与在实施例1步骤3中描述的方式类似的方式由(4-(二氟甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物49(20mg,35%)。1H NMR(400MHz,DMSO-d6)δ13.93(s,1H),8.87(s,1H),8.66(s,1H),8.27(d,J=7.5Hz,2H),7.76(d,J=7.5Hz,2H),7.72(d,J=8.0Hz,2H),7.09(d,J=8.1Hz,2H),3.28–3.21(m,4H),2.55–2.51(m,4H),2.29(s,3H).。LC-MS(M+H)+=420.22,Rt=10.496min。
实施例50:3-(4-(叔丁氧基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物50)
以与在实施例1步骤3中描述的方式类似的方式由(4-(叔丁氧基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物50(35mg,55%)。1H NMR(400MHz,DMSO-d6)δ13.67(s,1H),8.82(d,J=1.6Hz,1H),8.57(d,J=1.5Hz,1H),8.02(d,J=8.5Hz,2H),7.68(d,J=8.6Hz,2H),7.15(d,J=8.5Hz,2H),7.06(d,J=8.6Hz,2H),3.26–3.20(m,4H),2.54–2.51(m,4H),2.28(s,3H),1.39(s,9H).。LC-MS(M+H)+=442.24,Rt=11.335min。
实施例51:3-(4-(二氟甲氧基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物51)
以与在实施例1步骤3中描述的方式类似的方式由(4-(二氟甲氧基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物51(28mg,40%)。1H NMR(400MHz,DMSO-d6)δ13.83(s,1H),8.86(s,1H),8.61(s,1H),8.35–8.06(m,2H),7.84–7.62(m,2H),7.60–7.19(m,3H),7.08(d,J=6.2Hz,2H),3.28–3.19(m,4H),2.56–2.49(m,4H),2.28(s,3H).。LC-MS(M+H)+=436.20,Rt=10.557min。
实施例52:3-(4-(2H-四唑-5-基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物52)
以与在实施例1步骤3中描述的方式类似的方式由(4-(2H-四唑-5-基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物52(19mg,30%)。1H NMR(400MHz,DMSO-d6)1H NMR(400MHz,DMSO)δ13.92(s,1H),8.85(d,J=1.9Hz,1H),8.70(d,J=1.9Hz,1H),8.25(d,J=8.4Hz,2H),8.19(d,J=8.4Hz,2H),7.75(d,J=8.7Hz,2H),7.11(d,J=8.7Hz,2H),3.42–3.23(m,J=4.4Hz,4H),2.99–2.82(m,J=4.3Hz,4H),2.56(s,3H)。LC-MS(M+H)+=438.22,Rt=9.473min。
实施例53:3-(4-(1H-吡唑-1-基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物53)
以与在实施例1步骤3中描述的方式类似的方式由(4-(1H-吡唑-1-基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物53(25mg,40%)。1H NMR(400MHz,DMSO-d6)δ13.84(s,1H),8.85(s,1H),8.65(s,1H),8.56(s,1H),8.25(d,J=8.0Hz,2H),8.03(d,J=8.1Hz,2H),7.81(s,1H),7.71(d,J=8.1Hz,2H),7.08(d,J=8.1Hz,2H),6.60(s,1H),3.27–3.20(m,4H),2.53–2.42(m,4H),2.26(s,3H).。LC-MS(M+H)+=436.24,Rt=10.290min。
实施例54:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(吡咯烷-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物54)
以与在实施例1步骤3中描述的方式类似的方式由(4-(吡咯烷-1-基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物54(30mg,45%)。1H NMR(400MHz,DMSO-d6)δ13.48(s,1H),8.78(d,J=1.7Hz,1H),8.51(d,J=1.7Hz,1H),7.90(d,J=8.6Hz,2H),7.66(d,J=8.6Hz,2H),7.05(d,J=8.7Hz,2H),6.68(d,J=8.6Hz,2H),3.39–3.25(m,J=38.2Hz,8H),3.23–3.17(m,4H),2.25(s,3H),2.04–1.93(m,4H).。LC-MS(M+H)+=439.26,Rt=11.500min。
实施例55:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(吡咯烷-1-基磺酰基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物55)
以与在实施例1步骤3中描述的方式类似的方式由(4-(吡咯烷-1-基磺酰基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物55(12mg,35%)。1H NMR(400MHz,DMSO-d6)1HNMR(400MHz,DMSO)δ14.02(s,1H),8.86(d,J=0.7Hz,1H),8.68(s,1H),8.36(d,J=8.2Hz,2H),7.94(d,J=8.2Hz,2H),7.70(d,J=8.5Hz,2H),7.06(d,J=8.5Hz,2H),3.24–3.16(m,8H),2.50–2.39(m,4H),2.24(s,3H),1.88–1.53(m,4H)。LC-MS(M+H)+=503.21,Rt=10.199min。
实施例56:N,N-二乙基-3-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯甲酰胺(化合物56)
以与在实施例1步骤3中描述的方式类似的方式由(3-(二乙基氨基甲酰基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物56(16mg,30%)。1H NMR(400MHz,DMSO-d6)δ13.88(s,1H),8.86(s,1H),8.58(s,1H),8.19(d,J=7.3Hz,1H),8.01(s,1H),7.66(dd,J=21.3,7.8Hz,3H),7.42(d,J=7.1Hz,1H),7.08(d,J=7.8Hz,2H),3.31–3.28(m,4H),3.26–3.20(m,4H),2.53–2.45(m,4H),2.26(s,3H),1.18(s,6H).。LC-MS(M+H)+=469.31,Rt=10.279min。
实施例57:N,N-二甲基-3-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯基)甲胺(化合物57)
以与在实施例1步骤3中描述的方式类似的方式由(4-((二甲氨基)甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物57(29mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.81(s,1H),8.82(s,1H),8.59(s,1H),8.05(d,J=7.7Hz,2H),7.69(d,J=8.2Hz,2H),7.45(d,J=7.6Hz,2H),7.06(d,J=8.3Hz,2H),3.45(s,2H),3.27–3.15(m,4H),2.50–2.42(m,4H),2.23(s,3H),2.19(s,6H)。LC-MS(M+H)+=427.30,Rt=7.113min。
实施例58:1-(4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯基)环丙烷-1-甲腈(化合物58)
以与在实施例1步骤3中描述的方式类似的方式由(4-(1-乙炔基环丙基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物58(15mg,35%)。1H NMR(400MHz,DMSO-d6)δ13.81(s,1H),8.83(d,J=2.0Hz,1H),8.59(d,J=2.0Hz,1H),8.12(d,J=8.4Hz,2H),7.68(d,J=8.8Hz,2H),7.51(d,J=8.4Hz,2H),7.06(d,J=8.8Hz,2H),3.24–3.20(m,4H),2.51–2.44(m,4H),2.25(s,3H),1.82(q,J=4.8Hz,2H),1.59(q,J=5.1Hz,2H)。LC-MS(M+H)+=435.23,Rt=10.340min。
实施例59:3-(4-(苄氧基)-3-(三氟甲基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物59)
以与在实施例1步骤3中描述的方式类似的方式由(4-(苄氧基)-3-(三氟甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物59(16mg,35%)。1H NMR(400MHz,DMSO-d6)δ13.84(s,1H),8.84(s,1H),8.56(s,1H),8.37(d,J=8.0Hz,1H),8.27(s,1H),7.68(d,J=7.8Hz,2H),7.60–7.42(m,5H),7.39(d,J=6.8Hz,1H),7.07(d,J=7.8Hz,2H),5.39(s,2H),3.25–3.19(m,4H),2.52–2.45(m,4H),2.26(s,3H)。LC-MS(M+H)+=544.29,Rt=12.286min。
实施例60:3-(4-(苄氧基)-3-甲基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物60)
以与在实施例1步骤3中描述的方式类似的方式由(4-(苄氧基)-3-甲基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物60(25mg,40%)。1H NMR(400MHz,DMSO-d6)δ13.60(s,1H),8.78(d,J=1.9Hz,1H),8.52(d,J=1.9Hz,1H),7.86(d,J=6.5Hz,2H),7.65(d,J=8.7Hz,2H),7.50(d,J=7.3Hz,2H),7.41(t,J=7.4Hz,2H),7.33(t,J=7.3Hz,1H),7.16(d,J=9.1Hz,1H),7.04(d,J=8.7Hz,2H),5.21(s,2H),3.22–3.15(m,4H),2.50–2.41(m,4H),2.33(s,3H),2.23(s,3H)。LC-MS(M+H)+=490.32,Rt=12.245min。
实施例61:3-(4-(苄氧基)-3,5-二氟苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物61)
以与在实施例1步骤3中描述的方式类似的方式由(4-(苄氧基)-3,5-二氟苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物61(25mg,45%)。1H NMR(400MHz,DMSO-d6)δ8.84(d,J=1.8Hz,1H),8.63(d,J=1.8Hz,1H),7.81(d,J=9.2Hz,2H),7.71(d,J=8.6Hz,2H),7.49(d,J=7.0Hz,2H),7.45–7.28(m,3H),7.06(d,J=8.7Hz,2H),5.26(s,2H),3.24–3.21(m,4H),2.52–2.42(m,4H),2.26(s,3H)。LC-MS(M+H)+=512.26,Rt=12.131min。
实施例62:3-(4-环丙氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物62)
以与在实施例1步骤3中描述的方式类似的方式由(4-环丙氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物62(19mg,35%)。1H NMR(400MHz,DMSO-d6)δ13.62(s,1H),8.82(d,J=1.6Hz,1H),8.55(d,J=1.6Hz,1H),8.04(d,J=8.6Hz,2H),7.68(d,J=8.6Hz,2H),7.23(d,J=8.6Hz,2H),7.07(d,J=8.7Hz,2H),3.99–3.88(m,1H),3.27–3.15(m,4H),2.52–2.48(m,4H),2.27(s,3H),0.90–0.80(m,2H),0.76–0.65(m,J=7.8Hz,2H).。LC-MS(M+H)+=426.26,Rt=11.028min。
实施例63:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(吡啶-3-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物63)
以与在实施例1步骤3中描述的方式类似的方式由(4-(吡啶-3-基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物63(25mg,45%)。1H NMR(400MHz,DMSO-d6)δ13.80(s,1H),8.97(d,J=2.0Hz,1H),8.83(d,J=2.1Hz,1H),8.62(d,J=2.1Hz,1H),8.60(dd,J=4.7,1.5Hz,1H),8.23(d,J=8.4Hz,2H),8.18–8.06(m,1H),7.89(d,J=8.4Hz,2H),7.68(d,J=8.8Hz,2H),7.54–7.47(m,1H),7.06(d,J=8.8Hz,2H),3.21–3.16(m,4H),2.49–2.45(m,4H),2.24(s,3H)。LC-MS(M+H)+=447.26,Rt=9.901min。
实施例64:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(吡啶-4-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物64)
以与在实施例1步骤3中描述的方式类似的方式由(4-(吡啶-4-基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物64(20mg,40%)。1H NMR(400MHz,DMSO-d6)δ13.87(s,1H),8.84(s,1H),8.67(d,J=4.7Hz,2H),8.64(s,1H),8.25(d,J=8.0Hz,2H),7.97(d,J=8.0Hz,2H),7.77(d,J=4.8Hz,2H),7.69(d,J=8.4Hz,2H),7.06(d,J=8.4Hz,2H),3.24–3.20(m,4H),2.50–2.43(m,4H),2.24(s,3H)。LC-MS(M+H)+=447.26,Rt=9.212min。
实施例65:4-(4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苄基)吗啉(化合物65)
以与在实施例1步骤3中描述的方式类似的方式由(4-(吗啉甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物65(25mg,40%)。1H NMR(400MHz,DMSO-d6)δ13.74(s,1H),8.84(s,1H),8.60(s,1H),8.07(d,J=7.7Hz,2H),7.69(d,J=8.1Hz,2H),7.50(d,J=7.3Hz,2H),7.07(d,J=8.0Hz,2H),3.73–3.59(m,4H),3.56(s,2H),3.26–3.18(m,4H),2.57–2.50(m,4H),2.48–2.37(m,4H),2.27(s,3H)。LC-MS(M+H)+=469.31,Rt=7.144min。
实施例66:1-(3-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯基)乙酮(化合物66)
以与在实施例1步骤3中描述的方式类似的方式由(3-乙酰苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物66(25mg,40%)。1H NMR(400MHz,DMSO-d6)δ13.98(s,1H),8.86(s,1H),8.60(d,J=17.3Hz,2H),8.38(d,J=7.6Hz,1H),8.02(d,J=7.6Hz,1H),7.79–7.64(m,3H),7.07(d,J=8.6Hz,2H),3.26–3.16(m,4H),2.70(s,3H),2.51–2.43(m,J=5.1Hz,4H),2.25(s,3H)。LC-MS(M+H)+=412.22,Rt=10.014min。
实施例67:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(甲基磺酰基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物67)
以与在实施例1步骤3中描述的方式类似的方式由(4-(甲基磺酰基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物67(25mg,40%)。1H NMR(400MHz,DMSO-d6)δ14.16(s,1H),8.91(d,J=1.9Hz,1H),8.73(d,J=1.9Hz,1H),8.42(d,J=8.5Hz,2H),8.10(d,J=8.5Hz,2H),7.75(d,J=8.7Hz,2H),7.11(d,J=8.8Hz,2H),3.32(s,3H),3.29–3.21(m,4H),2.55–2.49(m,4H),2.29(s,3H).。LC-MS(M+H)+=448.20,Rt=9.045min。
实施例68:5-(4-(4-甲基哌嗪-1-基)苯基)-3-(4-(2,2,2-三氟乙氧基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物68)
以与在实施例1步骤3中描述的方式类似的方式由(4-(2,2,2-三氟乙氧基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物68(35mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.70(s,1H),8.83(s,1H),8.57(s,1H),8.09(d,J=8.1Hz,2H),7.69(d,J=8.0Hz,2H),7.26(d,J=8.1Hz,2H),7.08(d,J=8.0Hz,2H),4.85(dd,J=17.3,8.6Hz,2H),3.26–3.19(m,4H),2.54–2.46(m,4H),2.28(s,3H)。LC-MS(M+H)+=468.24,Rt=10.960min。
实施例69:2-(4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯基)-1,3,4-恶二唑(化合物69)
以与在实施例1步骤3中描述的方式类似的方式由(4-(1,3,4-恶二唑-2-基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物69(18mg,35%)。1H NMR(400MHz,DMSO-d6)δ14.01(s,1H),9.36(s,1H),8.87(s,1H),8.69(s,1H),8.37(d,J=7.9Hz,2H),8.20(d,J=7.8Hz,2H),7.72(d,J=8.0Hz,2H),7.08(d,J=8.1Hz,2H),3.28–3.20(m,4H),2.54–2.48(m,4H),2.28(s,3H)。LC-MS(M+H)+=438.18,Rt=9.610min。
实施例70:N,N-二乙基-4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯胺(化合物70)
以与在实施例1步骤3中描述的方式类似的方式由(4-(二乙氨基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物70(50mg,80%)。1H NMR(400MHz,DMSO-d6)δ13.50(s,1H),8.78(d,J=1.8Hz,1H),8.52(d,J=1.8Hz,1H),7.89(d,J=8.7Hz,2H),7.66(d,J=8.6Hz,2H),7.04(d,J=8.7Hz,2H),6.81(d,J=8.8Hz,2H),3.45–3.39(m,J=6.8Hz,4H),3.31–3.00(m,4H),2.53–2.40(m,4H),2.23(s,3H),1.13(t,J=6.9Hz,6H)。LC-MS(M+H)+=441.30,Rt=9.361min。
实施例71:3-(3,5-二氟-4-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物71)
以与在实施例1步骤3中描述的方式类似的方式由(3,5-二氟-4-甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物71(25mg,65%)。1H NMR(400MHz,DMSO-d6)δ13.98(s,1H),8.84(d,J=1.5Hz,1H),8.65(d,J=1.4Hz,1H),7.84(d,J=9.2Hz,2H),7.72(d,J=8.6Hz,2H),7.06(d,J=8.6Hz,2H),4.00(s,3H),3.28–3.13(m,J=4.1Hz,4H),2.50–2.43(m,J=4.4Hz,4H),2.24(s,3H)。LC-MS(M+H)+=436.20,Rt=10.892min。
实施例72:3-(4-甲氧基-3-(三氟甲基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物72)
以与在实施例1步骤3中描述的方式类似的方式由(4-甲氧基-3-(三氟甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物72(60mg,70%)。1H NMR(400MHz,DMSO-d6)δ13.87(s,1H),8.84(d,J=2.0Hz,1H),8.56(d,J=2.0Hz,1H),8.40(dd,J=8.7,1.9Hz,1H),8.21(d,J=1.9Hz,1H),7.68(d,J=8.7Hz,2H),7.43(d,J=8.7Hz,1H),7.07(d,J=8.8Hz,2H),3.98(s,3H),3.28–3.04(m,4H),2.50–2.40(m,4H),2.24(s,3H)。LC-MS(M+H)+=468.24,Rt=11.068min。
实施例73:3-(2-氟-4-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物73)
以与在实施例1步骤3中描述的方式类似的方式由(2-氟-4-甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物73(50mg,75%)。1H NMR(400MHz,DMSO-d6)δ13.90(s,1H),8.83(s,1H),8.27(s,1H),7.82(t,J=8.6Hz,1H),7.61(d,J=8.4Hz,2H),7.05(d,J=8.8Hz,3H),6.97(d,J=8.4Hz,1H),3.86(s,3H),3.28–3.07(m,4H),2.48–2.42(m,4H),2.23(s,3H)。LC-MS(M+H)+=418.21,Rt=10.356min。
实施例74:3-(4-甲氧基-2-(三氟甲基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物74)
以与在实施例1步骤3中描述的方式类似的方式由(4-甲氧基-2-(三氟甲基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物74(80mg,75%)。1H NMR(400MHz,DMSO-d6)δ13.85(s,1H),8.84(d,J=2.1Hz,1H),8.06(d,J=2.0Hz,1H),7.69(d,J=8.4Hz,1H),7.59(d,J=8.8Hz,2H),7.48–7.32(m,2H),7.02(d,J=8.8Hz,2H),3.93(s,3H),3.26–3.09(m,4H),2.50–2.39(m,4H),2.22(s,3H)。LC-MS(M+H)+=468.24,Rt=10.431min。
实施例75:3-(3-氯-4-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物75)
以与在实施例1步骤3中描述的方式类似的方式由(3-氯-4-甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物75(55mg,75%)。1H NMR(400MHz,DMSO-d6)δ13.83(s,1H),8.82(d,J=1.4Hz,1H),8.56(d,J=1.3Hz,1H),8.08(s,2H),7.68(d,J=8.5Hz,2H),7.30(d,J=9.1Hz,1H),7.06(d,J=8.6Hz,2H),3.94(s,3H),3.26–3.05(m,4H),2.50–2.37(m,J=4.2Hz,4H),2.23(s,3H)。LC-MS(M+H)+=434.23,Rt=10.745min。
实施例76:3-(2-氯-4-甲氧基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物76)
以与在实施例1步骤3中描述的方式类似的方式由(2-氯-4-甲氧基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物76(25mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.88(s,1H),8.83(d,J=2.1Hz,1H),8.14(d,J=2.1Hz,1H),7.60(t,J=8.1Hz,3H),7.24(d,J=2.5Hz,1H),7.09(dd,J=8.6,2.6Hz,1H),7.03(d,J=8.8Hz,2H),3.87(s,3H),3.27–3.12(m,4H),2.50–2.39(m,4H),2.22(s,3H)。LC-MS(M+H)+=434.19,Rt=10.411min。
实施例77:3-(4-(苄氧基)苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物77)
以与在实施例1步骤3中描述的方式类似的方式由(4-(苄氧基)苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物77(30mg,60%)。1H NMR(400MHz,DMSO-d6)δ13.71(s,1H),8.82(s,1H),8.56(s,1H),8.05(d,J=8.3Hz,2H),7.69(d,J=8.2Hz,2H),7.51(d,J=7.1Hz,2H),7.43(t,J=7.2Hz,2H),7.37(d,J=7.0Hz,1H),7.19(d,J=8.3Hz,2H),7.07(d,J=8.3Hz,2H),5.21(s,2H),3.26–3.13(m,4H),2.51–2.38(m,4H),2.24(s,3H)。LC-MS(M+H)+=476.28,Rt=11.717min。
实施例78:3-(4-(苄氧基)-3-氟苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物78)
以与在实施例1步骤3中描述的方式类似的方式由(4-(苄氧基)-3-氟苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物78(30mg,65%)。1H NMR(400MHz,DMSO-d6)δ13.83(s,1H),8.82(d,J=1.3Hz,1H),8.59(s,1H),8.03–7.82(m,2H),7.69(d,J=8.5Hz,2H),7.51(d,J=7.2Hz,2H),7.43(t,J=7.5Hz,2H),7.40–7.26(m,2H),7.06(d,J=8.5Hz,2H),5.27(s,2H),3.24–3.14(m,4H),2.50–2.41(m,J=4.2Hz,4H),2.23(s,3H)。LC-MS(M+H)+=494.27,Rt=11.750min。
实施例79:3-(4-甲氧基-3-甲基苯基)-5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶(化合物79)
以与在实施例1步骤3中描述的方式类似的方式由(4-甲氧基-3-甲基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物79(25mg,60%)。1H NMR(400MHz,DMSO-d6)δ13.68(s,1H),8.80(s,1H),8.54(s,1H),8.05–7.79(m,2H),7.66(d,J=7.6Hz,2H),7.07(dd,J=15.3,8.4Hz,3H),3.86(s,3H),3.19(s,4H),2.46(s,4H),2.28(s,3H),2.23(s,3H)。LC-MS(M+H)+=414.19,Rt=10.829min。
实施例80:N,N,2-三甲基-4-(5-(4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-b]吡啶-3-基)苯甲酰胺(化合物80)
以与在实施例1步骤3中描述的方式类似的方式由(4-(二甲基氨基甲酰基)-3-甲基苯基)硼酸和化合物1-2(100mg,1.0eq)制备化合物80(20mg,50%)。1H NMR(400MHz,DMSO-d6)δ13.88(s,1H),8.83(d,J=1.7Hz,1H),8.62(d,J=1.7Hz,1H),7.96(d,J=6.8Hz,2H),7.69(d,J=8.6Hz,2H),7.31(d,J=8.3Hz,1H),7.07(d,J=8.7Hz,2H),3.24–3.15(m,4H),3.04(s,3H),2.83(s,3H),2.49–2.42(m,4H),2.32(s,3H),2.23(s,3H)。LC-MS(M+H)+=455.27,Rt=9.473min。
生物学测定
I.HPK1激酶结合测定
在基于时间分辨荧光共振能量转移方法的结合测定中,测试本文公开的化合物对HPK1激酶(aa1-346,Life Technologies)的抑制。将重组HPK1(5nM)与本文公开的化合物或DMSO一起在室温下在含有50mM HEPES pH 7.5、10mM MgCl2、1mM EGTA、0.01%Brij-35的测定缓冲液中预孵育1小时。并且然后将Tracer222(Life Technologies)和Eu-Anti-GST抗体(cisbio)添加到板中,并且在室温下进一步孵育1h。在BMG PHERAstar FS仪器上读取TR-FRET信号(ex337nm,em 620nm/665nm)。基于在665nm处的荧光与在620nm处的荧光的比率计算在递增浓度的化合物的存在下对HPK1的抑制。通过Graphpad Prism软件将数据拟合到四参数逻辑方程得出每种化合物的IC50。本文公开的化合物显示酶结合值,如表1所示。
表1.本文公开的化合物在100nM时的酶抑制率(%)
注:A=70%-90%,B=50%-70%,C=%30-50%,D=10%-20%,E<10%
II.在1mM ATP的HPK激酶活性测定
在基于时间分辨荧光共振能量转移(TR-FRET)方法的测定中,测试本文公开的化合物对HPK1激酶(aa1-346,Life Technologies)活性的抑制。在384孔低容量黑色板中在含有50mM HEPES、0.01%BSA、0.1mM原钒酸盐、10mM MgCl2、1mM DTT,pH=7.0,0.005%Tween-20的缓冲液中的含有HPK1激酶(40nM)、1mM ATP、0.5μM STK1底物和0-10μM化合物的反应混合物中进行测定。将激酶与本文公开的化合物或DMSO一起在室温下孵育60分钟,并且通过添加ATP和STK1底物引发反应。在室温下反应120分钟之后,根据制造商的说明书(CisBio)添加等体积的终止/检测溶液。所述终止/检测溶液含有在检测缓冲液中的STK抗体-穴状化合物(Cryptate)和XL665-缀合的链霉亲和素。在PHERAstar FS读板器(BMG Labtech)上记录TR-FRET信号(在337nm波长处的激发的情况下在665nm处的荧光发射与在620nm处的发射的比率)。STK1底物的磷酸化导致STK抗体-穴状化合物与生物素化的STK1底物结合,这将荧光供体(Eu3+穴状化合物)置于与受体(链霉亲和素-XL665)密切接近,从而导致高的荧光共振能量转移程度。基于在665nm处的荧光与在620nm处的荧光的比率计算在递增浓度的化合物的存在下对HPK1的抑制。通过Graphpad Prism软件将数据拟合到四参数逻辑方程得出每种化合物的IC50。本文公开的化合物显示酶活性值,如表2所示。
表2.本文公开的化合物在100nM时的酶抑制率(%)
化合物编号 | 抑制率/% | 化合物编号 | 抑制率% | 化合物编号 | 抑制率% |
61 | B | 69 | D | 77 | E |
62 | B | 70 | D | 78 | A |
63 | B | 71 | D | 79 | B |
64 | B | 72 | E | 80 | D |
65 | B | 73 | E | ||
66 | A | 74 | B | ||
67 | A | 75 | A | ||
68 | A | 76 | B |
注:A=70%-90%,B=50%-70%,C=%30-50%,D=10%-20%,E<10%
尽管为了理解清楚的目的,已经通过说明和实施例详细地描述了前述发明,但是对于本领域技术人员清楚的是,可以实施某些较小的改变和修改。因此,描述和实施例不应被解释为限制本发明的范围。
Claims (10)
1.一种如式(Ⅰ)所示结构的化合物、其立体异构体或其药学上可接受的盐;
其中:
L1是单键、亚烷基、亚环烷基、*1-O-亚烷基-**1、*1-亚烷基-O-**1、*1-NH-亚烷基-**1、*1-亚烷基-NH-**1、*1-NHC(O)-**1、*1-C(O)NH-**1、亚烯基或亚炔基,其中*1是指与Cy1附接的位置,并且**1是指与附接的位置;
Cy1是包含一个或两个独立地选自氮、氧或任选氧化的硫中的杂原子作为一个或多个环成员的5或6元杂环基,并且在所述杂环是6元环时,R1相对于附接点L1在所述杂环基的对位处;或者Cy1是包含一或二或三个独立地选自氮、氧或任选氧化的硫中的杂原子作为一个或多个环成员的7至10元双环稠合的杂环基;
R1是卤素、-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基、杂芳基、氧代基、-CN、-NO2、-OR1a、-SO2R1a、-SO2NR1aR1b、-COR1a、-CO2R1a、-CONR1aR1b、-C(=NR1a)NR1bR1c、-NR1aR1b、-NR1aCOR1b、-NR1aCONR1bR1c、-NR1aCO2R1b、-NR1aSONR1bR1c、-NR1aSO2NR1bR1c或-NR1aSO2R1b,所述-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基或杂芳基各自任选地被至少一个取代基R1d取代;
R1a、R1b和R1c各自独立地是氢、-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基或杂芳基,所述-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基、或杂芳基各自任选地被至少一个取代基R1e取代;或者(R1a和R1b)、(R1b和R1c)或(R1c和R1a)与它们所附接的一个或多个原子一起形成3至12元环,所述环包含0、1或2个独立地选自氮、氧或任选氧化的硫中的杂原子作为一个或多个环成员,所述环任选地被至少一个取代基R1e取代;
R1d和R1e各自独立地是氢、卤素、-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基、杂芳基、氧代基、-CN、-NO2、-OR1f、-SO2R1f、-SO2NR1fR1g、-COR1f、-CO2R1f、-CONR1fR1g、-C(=NR1f)NR1gR1h、-NR1fR1g、-NR1fCOR1g、-NR1fCONR1gR1h、-NR1fCO2R1f、-NR1fSONR1fR1g、-NR1fSO2NR1gR1h或-NR1fSO2R1g,所述-C1-8烷基、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基、或杂芳基各自任选地被至少一个选自卤素、-C1-8烷基、-OR1i、-NR1iR1j、环烷基、杂环基、芳基、或杂芳基的取代基取代;
R1f、R1g、R1h、R1i、和R1j各自独立地是氢、-C1-8烷基、C1-8烷氧基-C1-8烷基-、-C2-8烯基、-C2-8炔基、环烷基、杂环基、芳基或杂芳基。
2.根据权利要求1所述的化合物、其立体异构体或其药学上可接受的盐,其特征在于,所述的6元杂环基是哌啶基、四氢吡啶基或哌嗪基。
3.根据权利要求1所述的化合物、其立体异构体或其药学上可接受的盐,其特征在于,所述的7至10元双环稠合杂环基是二氢吡啶并噁嗪、二氢苯并氧氮杂卓基、异吲哚啉基、二氢异喹啉基、四氢异喹啉基、苯并氮杂卓基、苯并氧氮杂卓基或二氢苯并噁嗪。
8.一种药物组合物,其特征在于,包含治疗有效量的如权利要求1-4任一项所述的化合物、其立体异构体或其药学上可接受的盐,以及药学上可接受的赋形剂或载体。
9.一种如权利要求1-4任一项所述的化合物、其立体异构体或其药学上可接受的盐作为HPK1抑制剂在制备用于治疗HPK1相关障碍或疾病的药物中的应用。
10.根据权利要求9所述的应用,其特征在于,所述的HPK1相关障碍或疾病选自结肠直肠癌、黑色素瘤、非小细胞肺癌、卵巢癌、乳腺癌、胰腺癌、血液系统恶性肿瘤和肾细胞癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110966463.3A CN113861188B (zh) | 2021-08-23 | 2021-08-23 | 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110966463.3A CN113861188B (zh) | 2021-08-23 | 2021-08-23 | 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113861188A true CN113861188A (zh) | 2021-12-31 |
CN113861188B CN113861188B (zh) | 2023-02-28 |
Family
ID=78988107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110966463.3A Active CN113861188B (zh) | 2021-08-23 | 2021-08-23 | 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113861188B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114940683A (zh) * | 2022-07-26 | 2022-08-26 | 轩竹(北京)医药科技有限公司 | Hpk1抑制剂及其用途 |
US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
CN116162087A (zh) * | 2023-02-20 | 2023-05-26 | 杭州医学院 | 一种hpk 1和/或lck激酶调节剂、制备方法及其应用 |
WO2023250335A1 (en) * | 2022-06-21 | 2023-12-28 | Chulalongkorn University | 1,4-diphenyl-1 h-indazole and 1-pyridin-2-yl-4-phenyl-1 h-indazole derivatives as pd-1/pd-l1 modulators for the treatment of cancer |
US11897878B2 (en) | 2018-10-31 | 2024-02-13 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11925631B2 (en) | 2018-10-31 | 2024-03-12 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160200722A1 (en) * | 2013-08-22 | 2016-07-14 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2018049214A9 (en) * | 2016-09-09 | 2018-10-18 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
CN109923114A (zh) * | 2016-09-09 | 2019-06-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
CN110402248A (zh) * | 2017-03-15 | 2019-11-01 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
TW202102500A (zh) * | 2019-03-26 | 2021-01-16 | 比利時商健生藥品公司 | 二環hpk1抑制劑 |
CN113166139A (zh) * | 2018-11-22 | 2021-07-23 | 百济神州有限公司 | 作为HPK1抑制剂的吡咯并[2,3-b]吡啶及其用途 |
-
2021
- 2021-08-23 CN CN202110966463.3A patent/CN113861188B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160200722A1 (en) * | 2013-08-22 | 2016-07-14 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2018049214A9 (en) * | 2016-09-09 | 2018-10-18 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
CN109923114A (zh) * | 2016-09-09 | 2019-06-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
CN110402248A (zh) * | 2017-03-15 | 2019-11-01 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
CN113166139A (zh) * | 2018-11-22 | 2021-07-23 | 百济神州有限公司 | 作为HPK1抑制剂的吡咯并[2,3-b]吡啶及其用途 |
TW202102500A (zh) * | 2019-03-26 | 2021-01-16 | 比利時商健生藥品公司 | 二環hpk1抑制劑 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11897878B2 (en) | 2018-10-31 | 2024-02-13 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11925631B2 (en) | 2018-10-31 | 2024-03-12 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
WO2023250335A1 (en) * | 2022-06-21 | 2023-12-28 | Chulalongkorn University | 1,4-diphenyl-1 h-indazole and 1-pyridin-2-yl-4-phenyl-1 h-indazole derivatives as pd-1/pd-l1 modulators for the treatment of cancer |
CN114940683A (zh) * | 2022-07-26 | 2022-08-26 | 轩竹(北京)医药科技有限公司 | Hpk1抑制剂及其用途 |
CN114940683B (zh) * | 2022-07-26 | 2023-01-17 | 轩竹(北京)医药科技有限公司 | Hpk1抑制剂及其用途 |
CN116162087A (zh) * | 2023-02-20 | 2023-05-26 | 杭州医学院 | 一种hpk 1和/或lck激酶调节剂、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113861188B (zh) | 2023-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113861188B (zh) | 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用 | |
AU2017342022B2 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | |
AU2018201557B2 (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity | |
JP5808869B2 (ja) | 二環式ピペラジン化合物 | |
JP2021514359A (ja) | キナーゼ阻害剤としての複素環式化合物 | |
WO2014139326A1 (en) | Pyrazolo compounds and uses thereof | |
CN106928219B (zh) | 含氮稠杂环化合物、制备方法、中间体、组合物和应用 | |
JP6564406B2 (ja) | カゼインキナーゼ1デルタ/イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体 | |
CN114502536A (zh) | 作为激酶抑制剂的杂环化合物 | |
CN110872296B (zh) | 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用 | |
CN103517903A (zh) | 作为mps1抑制剂的吡咯并吡啶氨基衍生物 | |
EP4321515A1 (en) | Ubiquitin-specific protease 1 (usp1) inhibitor | |
AU2016333508A1 (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual DYRK1/CLK1 inhibitors | |
CA3124678A1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
EA022753B1 (ru) | Имидазотиадиазолы для применения в качестве ингибиторов киназ | |
KR20210151833A (ko) | Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체 | |
US20210147431A1 (en) | Pyrrolotriazine compounds and methods of inhibiting tam kinases | |
CN108264512B (zh) | 含氮稠杂环化合物、其制备方法、中间体、组合物和应用 | |
JP2021503479A (ja) | 置換ヘテロアリール化合物及び使用方法 | |
JP6576553B2 (ja) | 新規5H−ピロロ[2,3−d]ピリミジン−6(7H)−オン誘導体 | |
KR20220051226A (ko) | 아자헤테로아릴 화합물 및 이의 용도 | |
JPWO2018097234A1 (ja) | 新規オキソイソキノリン誘導体 | |
KR20220085735A (ko) | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 | |
EP4055013A1 (en) | Wdr5 inhibitors and modulators | |
WO2024097172A1 (en) | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |